{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:08:20Z","timestamp":1780628900695,"version":"3.54.1"},"reference-count":33,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Recent evidence regarding the healthcare resource utilization (HCRU) and associated costs of acromegaly is limited.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            This retrospective, cross-sectional administrative claims analysis (IQVIA Pharmetrics Plus\n            <jats:sup>\u00ae<\/jats:sup>\n            ) identified patients (\u226518\u00a0years) with acromegaly between 1 January 2017 and 30 June 2022. HCRU and costs over 1\u00a0year were compared in patients with acromegaly and matched patients without acromegaly (age, sex, insurance type, year). Among patients with acromegaly, annual total healthcare costs of comorbidities and procedures consistent with high-risk comorbidities were reported. Costs were adjusted to 2023 USD.\n            <jats:bold>Results:<\/jats:bold>\n            Among 2289 patients with acromegaly and 2289 matched patients without acromegaly, mean age was 49.8\u00a0years and 51.6% were female. Patients with acromegaly had a significantly (p\u00a0&lt;\u00a00.001) higher comorbidity burden than patients without acromegaly. A significantly (p\u00a0&lt;\u00a00.001) greater proportion of patients with acromegaly versus patients without acromegaly had inpatient hospitalizations (20.1 vs 4.9%) and emergency department visits (23.9 vs 15.7%). Total mean healthcare costs were also significantly higher for patients with acromegaly than patients without acromegaly ($51,888 vs $10,601). The majority of acromegaly-related healthcare costs ($30,985) were attributable to acromegaly therapy ($25,895). Hypertension (42.8%) was the most common high-risk comorbidity associated with acromegaly. The costliest high-risk comorbidity was congestive heart failure, with a mean cost difference of $38,123 (p\u00a0&lt;\u00a00.05) between patients with acromegaly with and without hypertension.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Patients with acromegaly had higher HCRU and costs than matched patients without acromegaly, and the presence of acromegaly with high-risk comorbidities was associated with a substantial HCRU and cost burden. This high burden of illness may be alleviated with better disease control.\n          <\/jats:p>","DOI":"10.57264\/cer-2025-0069","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T10:38:57Z","timestamp":1751971137000},"source":"Crossref","is-referenced-by-count":4,"title":["Healthcare utilization and costs among patients with acromegaly in the United States"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-4285","authenticated-orcid":false,"given":"Tiffany P","family":"Quock","sequence":"first","affiliation":[{"name":"Crinetics Pharmaceuticals, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-6153","authenticated-orcid":false,"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7110-9463","authenticated-orcid":false,"given":"Ashis K","family":"Das","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-1384","authenticated-orcid":false,"given":"Amanda","family":"Speller","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0818-5113","authenticated-orcid":false,"given":"Marian H","family":"Tarbox","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5958-4946","authenticated-orcid":false,"given":"Melinda L","family":"Rossi","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3567-0862","authenticated-orcid":false,"given":"Stacy K","family":"Rattana","sequence":"additional","affiliation":[{"name":"Crinetics Pharmaceuticals, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3591-7293","authenticated-orcid":false,"given":"Ingrid E","family":"Paulson","sequence":"additional","affiliation":[{"name":"Crinetics Pharmaceuticals, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-5536","authenticated-orcid":false,"given":"Michael S","family":"Broder","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1009965803750","article-title":"Epidemiology of acromegaly","volume":"2","author":"Holdaway IM","year":"1999","unstructured":"Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 2(1), 29\u201341 (1999).","journal-title":"Pituitary"},{"issue":"1","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-017-0166-6","article-title":"The association between biochemical control and cardiovascular risk factors in acromegaly","volume":"17","author":"Carmichael JD","year":"2017","unstructured":"Carmichael JD, Broder MS, Cherepanov D The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr. Disord. 17(1), (2017).","journal-title":"BMC Endocr. Disord."},{"issue":"1","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao A","year":"2004","unstructured":"Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102\u2013152 (2004).","journal-title":"Endocr. Rev."},{"key":"e_1_3_7_6_2","volume-title":"Endotext","author":"Carroll PV","year":"2000","unstructured":"Carroll PV, Joshi MN. Acromegaly. In: Endotext. Feingold KR, Ahmed SF, Anawalt Bet al. (Eds)., MDText.com, Inc, MA, USA (2000)."},{"issue":"8","key":"e_1_3_7_7_2","first-page":"2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group","volume":"83","author":"Orme SM","year":"1998","unstructured":"Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J. Clin. Endocrinol. Metab. 83(8), 2730\u20132734 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1172-3-17","article-title":"Acromegaly","volume":"3","author":"Chanson P","year":"2008","unstructured":"Chanson P, Salenave S. Acromegaly. Orphanet. J. Rare Dis. 3(1), 17 (2008).","journal-title":"Orphanet. J. Rare Dis."},{"issue":"5","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.beem.2009.05.010","article-title":"Acromegaly","volume":"23","author":"Chanson P","year":"2009","unstructured":"Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J. Acromegaly. Best Pract. Res. Clin. Endocrinol. Metab. 23(5), 555\u2013574 (2009).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"24","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Acromegaly","volume":"355","author":"Melmed S","year":"2006","unstructured":"Melmed S. Acromegaly. N. Engl. J. Med. 355(24), 2558\u20132573 (2006).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed S","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P A consensus statement on acromegaly therapeutic outcomes. Nature Rev. Endocrinol. 14(9), 552\u2013561 (2018).","journal-title":"Nature Rev. Endocrinol."},{"issue":"1","key":"e_1_3_7_12_2","first-page":"29","article-title":"Canadian consensus guidelines for the diagnosis and management of acromegaly","volume":"29","author":"Ezzat S","year":"2006","unstructured":"Ezzat S, Serri O, Chik CL Canadian consensus guidelines for the diagnosis and management of acromegaly. Clin. Invest. Med. 29(1), 29\u201339 (2006).","journal-title":"Clin. Invest. Med."},{"issue":"5","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael JD","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nu\u00f1o M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J. Clin. Endocrinol. Metab. 99(5), 1825\u20131833 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao A","year":"2016","unstructured":"Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19(3), 235\u2013247 (2016).","journal-title":"Pituitary"},{"issue":"4","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina A","year":"2014","unstructured":"Giustina A, Chanson P, Kleinberg D Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10(4), 243\u2013248 (2014).","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"bvad104","DOI":"10.1210\/jendso\/bvad104","article-title":"Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: a real-world analysis","volume":"7","author":"Fleseriu M","year":"2023","unstructured":"Fleseriu M, Barkan A, Brue T Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: a real-world analysis. J. Endocrine Soc. 7(10), bvad104 (2023).","journal-title":"J. Endocrine Soc."},{"issue":"3","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/pathophysiology30030029","article-title":"Acromegaly: pathophysiological considerations and treatment options including the evolving role of oral somatostatin analogs","volume":"30","author":"Daniel CP","year":"2023","unstructured":"Daniel CP, Wagner MJ, Borne GE Acromegaly: pathophysiological considerations and treatment options including the evolving role of oral somatostatin analogs. Pathophysiology 30(3), 377\u2013388 (2023).","journal-title":"Pathophysiology"},{"issue":"1","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/13696998.2021.1898968","article-title":"Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care","volume":"24","author":"Ribeiro-Oliveira A","year":"2021","unstructured":"Ribeiro-Oliveira A, Brook RA, Munoz KA Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care. J. Med. Econ. 24(1), 432\u2013439 (2021).","journal-title":"J. Med. Econ."},{"issue":"12","key":"e_1_3_7_19_2","first-page":"1106","article-title":"Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis","volume":"21","author":"Placzek H","year":"2015","unstructured":"Placzek H, Xu Y, Mu Y, Begelman SM, Fisher M. Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. J. Manag. Care Spec. Pharm. 21(12), 1106\u20131112 (2015).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"3","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11102-012-0432-6","article-title":"Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases","volume":"16","author":"Burton T","year":"2013","unstructured":"Burton T, Le Nestour E, Bancroft T, Neary M. Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary 16(3), 354\u2013362 (2013).","journal-title":"Pituitary"},{"issue":"2","key":"e_1_3_7_21_2","first-page":"S38","article-title":"Natural history and real-world data in rare diseases: applications, limitations, and future perspectives","volume":"62","author":"Liu J","year":"2022","unstructured":"Liu J, Barrett JS, Leonardi ET Natural history and real-world data in rare diseases: applications, limitations, and future perspectives. J. Clin. Pharmacol. 62(Suppl. 2), S38\u2013S55 (2022).","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/20476965.2019.1581433","article-title":"Key considerations when using health insurance claims data in advanced data analyses: an experience report","volume":"9","author":"Konrad R","year":"2019","unstructured":"Konrad R, Zhang W, Bjarnd\u00f3ttir M, Proa\u00f1o R. Key considerations when using health insurance claims data in advanced data analyses: an experience report. Health Syst. (Basingstoke) 9(4), 317\u2013325 (2019).","journal-title":"Health Syst. (Basingstoke)"},{"issue":"5","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejvs.2018.06.001","article-title":"The strengths and limitations of claims based research in countries with fee for service reimbursement","volume":"56","author":"Behrendt C-A","year":"2018","unstructured":"Behrendt C-A, Debus ES, Mani K, Sedrakyan A. The strengths and limitations of claims based research in countries with fee for service reimbursement. Eur. J. Vasc. Endovasc. Surg. 56(5), 615\u2013616 (2018).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"e_1_3_7_24_2","unstructured":"Bureau of Labor Statistics. Consumer price index medical care 2014\u20132024 (2024). Available at: https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM?output_view=data"},{"issue":"4","key":"e_1_3_7_25_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11102-013-0506-0","article-title":"Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases","volume":"17","author":"Broder MS","year":"2014","unstructured":"Broder MS, Neary MP, Chang E, Cherepanov D, Katznelson L. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary 17(4), 333\u2013341 (2014).","journal-title":"Pituitary"},{"issue":"10","key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.eprac.2021.04.412","article-title":"Health benefit costs and absenteeism among employed patients with acromegaly","volume":"27","author":"Yuen KCJ","year":"2021","unstructured":"Yuen KCJ, Munoz KA, Brook RA Health benefit costs and absenteeism among employed patients with acromegaly. Endocr. Pract. 27(10), 1034\u20131039 (2021).","journal-title":"Endocr. Pract."},{"issue":"3","key":"e_1_3_7_27_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40801-015-0039-0","article-title":"Treatment patterns and economic burden in patients treated for acromegaly in the USA","volume":"2","author":"Chuang C-C","year":"2015","unstructured":"Chuang C-C, Bhurke S, Chen S-Y, Dinet J, Brulais S, Gabriel S. Treatment patterns and economic burden in patients treated for acromegaly in the USA. Drugs \u2013 Real World Outcomes 2(3), 299\u2013309 (2015).","journal-title":"Drugs \u2013 Real World Outcomes"},{"issue":"6","key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/cen.14828","article-title":"The prevalence of acromegaly is higher than previously reported: changes over a three-decade period","volume":"97","author":"Aagaard C","year":"2022","unstructured":"Aagaard C, Christophersen AS, Finnerup S The prevalence of acromegaly is higher than previously reported: changes over a three-decade period. Clin. Endocrinol. 97(6), 773\u2013782 (2022).","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.14310\/horm.2002.1680","article-title":"Therapeutic trends and outcome of acromegaly: a single center experience over a 40-year period","volume":"15","author":"Karapanou O","year":"2016","unstructured":"Karapanou O, Tzanela M, Christoforaki M Therapeutic trends and outcome of acromegaly: a single center experience over a 40-year period. Hormones 15(3), 368\u2013376 (2016).","journal-title":"Hormones"},{"issue":"9","key":"e_1_3_7_30_2","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s40618-024-02321-6","article-title":"Recurrence in acromegaly: two tertiary centers experience and review of the literature","volume":"47","author":"Cremaschi A","year":"2024","unstructured":"Cremaschi A, Sala E, Lavezzi E Recurrence in acromegaly: two tertiary centers experience and review of the literature. J. Endocrinol. Invest. 47(9), 2269\u20132277 (2024).","journal-title":"J. Endocrinol. Invest."},{"issue":"2","key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jocn.2010.10.003","article-title":"Treatment of persistent and recurrent acromegaly","volume":"18","author":"Del Porto LA","year":"2011","unstructured":"Del Porto LA, Liubinas SV, Kaye AH. Treatment of persistent and recurrent acromegaly. J. Clin. Neurosci. 18(2), 181\u2013190 (2011).","journal-title":"J. Clin. Neurosci."},{"issue":"3","key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"e00158","DOI":"10.1002\/edm2.158","article-title":"Management of persistent acromegaly following primary therapy: the current landscape in the UK","volume":"3","author":"Kyriakakis N","year":"2020","unstructured":"Kyriakakis N, Seejore K, Hanafy A, Murray RD. Management of persistent acromegaly following primary therapy: the current landscape in the UK. Endocrinol. Diabetes Metab. 3(3), e00158 (2020).","journal-title":"Endocrinol. Diabetes Metab."},{"issue":"7","key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4158\/EP-2018-0040","article-title":"Necessity of multimodal treatment of acromegaly and outcomes","volume":"24","author":"Donegan DM","year":"2018","unstructured":"Donegan DM, I\u00f1iguez-Ariza N, Sharma A Necessity of multimodal treatment of acromegaly and outcomes. Endocr. Pract. 24(7), 668\u2013676 (2018).","journal-title":"Endocr. Pract."},{"issue":"3","key":"e_1_3_7_34_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11102-015-0701-2","article-title":"Incidence and prevalence of acromegaly in a large US health plan database","volume":"19","author":"Burton T","year":"2016","unstructured":"Burton T, Le Nestour E, Neary M, Ludlam WH. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary 19(3), 262\u2013267 (2016).","journal-title":"Pituitary"},{"issue":"11","key":"e_1_3_7_35_2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4158\/EP161397.OR","article-title":"Incidence and prevalence of acromegaly in the United States: a claims-based analysis","volume":"22","author":"Broder MS","year":"2016","unstructured":"Broder MS, Chang E, Cherepanov D, Neary MP, Ludlam WH. Incidence and prevalence of acromegaly in the United States: a claims-based analysis. Endocr. Pract. 22(11), 1327\u20131335 (2016).","journal-title":"Endocr. Pract."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:53:22Z","timestamp":1756457602000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.57264\/cer-2025-0069"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0069","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"e250069"}}